Contact
searchSearch
HMP Global
Login

Tardive Dyskinesia Topic Center

Patient survey
News
Patient Survey Identifies Barriers to TD Treatment
11/06/2024
Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according to a survey of adults with TD symptoms.
Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according to a survey of adults with TD symptoms.
Key barriers to tardive...
11/06/2024
Psych Congress Network
: FDA Approves Oral Valbenazine Granule Formulation, an Alternative Administration Option for Adults With TD
News
FDA Approves Oral Valbenazine Granule Formulation, an Alternative Administration Option for Adults With TD
05/15/2024
At the end of April, Neurocrine Biosciences, Inc. announced the approval of INGREZZA® SPRINKLE (valbenazine) capsules by the FDA. This approval provides an alternative option for patients with dysphagia or who have difficulty swallowing. 
At the end of April, Neurocrine Biosciences, Inc. announced the approval of INGREZZA® SPRINKLE (valbenazine) capsules by the FDA. This approval provides an alternative option for patients with dysphagia or who have difficulty swallowing. 
At the end of April, Neurocrine...
05/15/2024
Psych Congress Network
TD Has ‘Severe Impact’ on Patients and Caregivers
News
TD Has ‘Severe Impact’ on Patients and Caregivers
05/10/2024
Tardive dyskinesia (TD) was found to have a “severe impact” on the lives of both patients and their caregivers across physical, psychological, and social domains. Results from the survey-based study were published in the Journal of Patient...
Tardive dyskinesia (TD) was found to have a “severe impact” on the lives of both patients and their caregivers across physical, psychological, and social domains. Results from the survey-based study were published in the Journal of Patient...
Tardive dyskinesia (TD) was...
05/10/2024
Psych Congress Network
Geriatric Patient with son in long term care setting
News
High Comorbidity, Polypharmacy Burden in Patients With Tardive Dyskinesia in LTC Settings
05/07/2024
Patients with tardive dyskinesia (TD) in long-term care settings have a high comorbidity and polypharmacy burden, with half taking medications that may worsen TD, according to a poster presentation at the APA annual meeting.
Patients with tardive dyskinesia (TD) in long-term care settings have a high comorbidity and polypharmacy burden, with half taking medications that may worsen TD, according to a poster presentation at the APA annual meeting.
Patients with tardive dyskinesia...
05/07/2024
Psych Congress Network
Amber Hoberg, MSN, APRN, PMHNP-BC
Videos
Clinical Pearls to Enhance Tardive Dyskinesia Treatment
01/10/2024
n this video, Tardive Dyskinesia Section Editor Amber Hoberg, MSN, APRN, PMHNP-BC, of Med Management Associates, offers clinical pearls that clinicians can implement to optimize their tardive dyskinesia care.
n this video, Tardive Dyskinesia Section Editor Amber Hoberg, MSN, APRN, PMHNP-BC, of Med Management Associates, offers clinical pearls that clinicians can implement to optimize their tardive dyskinesia care.
n this video, Tardive Dyskinesia...
01/10/2024
Psych Congress Network
amber hoberg, np
Expert Insights Quiz
What screeners should be used to diagnose tardive dyskinesia?
05/26/2023
True or False: According to Nurse Amber Hoberg, the AIMS is the only scale that should be used when screening a patient for tardive dyskinesia (TD).
True or False: According to Nurse Amber Hoberg, the AIMS is the only scale that should be used when screening a patient for tardive dyskinesia (TD).
True or False: According to...
05/26/2023
Psych Congress Network
Elderly patient and his doctor
News
Awareness of TD Symptoms Linked With Poorer Health, Social Functioning in Patients
05/15/2023
Clinician-confirmed possible tardive dyskinesia (TD) was associated with diminished wellness and social functioning in real-world patients, according to a study published online in the Journal of Patient-Reported Outcomes.
Clinician-confirmed possible tardive dyskinesia (TD) was associated with diminished wellness and social functioning in real-world patients, according to a study published online in the Journal of Patient-Reported Outcomes.
Clinician-confirmed possible...
05/15/2023
Psych Congress Network
quiz
Expert Insights Quiz
How does tardive dyskinesia impact medication adherence?
02/14/2023
True or false: Patients with Tardive Dyskinesia (TD) have high rates of antipsychotic medication non-adherence partly due to their TD symptoms.
True or false: Patients with Tardive Dyskinesia (TD) have high rates of antipsychotic medication non-adherence partly due to their TD symptoms.
True or false: Patients with...
02/14/2023
Psych Congress Network
Chepke
Expert Insights Quiz
What is the next step if a patient taking antipsychotics exhibits excessive blink rate?
12/16/2022
As a clinician, if you notice a patient who is taking antipsychotics is exhibiting an excessive blink rate, what should the next step be?
As a clinician, if you notice a patient who is taking antipsychotics is exhibiting an excessive blink rate, what should the next step be?
As a clinician, if you notice a...
12/16/2022
Psych Congress Network
Tardive Dyskinesia
Conference Coverage
MIND-TD Questionnaire Developed as New Clinical Tool to Screen for Tardive Dyskinesia
06/04/2022
An interdisciplinary team of HCPs has developed the MIND-TD questionnaire to improve TD screening. They presented their development and revision process at Psych Congress Elevate 2022 in Las Vegas, Nevada.
An interdisciplinary team of HCPs has developed the MIND-TD questionnaire to improve TD screening. They presented their development and revision process at Psych Congress Elevate 2022 in Las Vegas, Nevada.
An interdisciplinary team of...
06/04/2022
Psychiatry & Behavioral Health
From Psychiatry & Behavioral Health

News Articles

Patient survey
News
Patient Survey Identifies Barriers to TD Treatment
11/06/2024
Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according to a survey of adults with TD symptoms.
Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according to a survey of adults with TD symptoms.
Key barriers to tardive...
11/06/2024
Psych Congress Network
: FDA Approves Oral Valbenazine Granule Formulation, an Alternative Administration Option for Adults With TD
News
FDA Approves Oral Valbenazine Granule Formulation, an Alternative Administration Option for Adults With TD
05/15/2024
At the end of April, Neurocrine Biosciences, Inc. announced the approval of INGREZZA® SPRINKLE (valbenazine) capsules by the FDA. This approval provides an alternative option for patients with dysphagia or who have difficulty swallowing. 
At the end of April, Neurocrine Biosciences, Inc. announced the approval of INGREZZA® SPRINKLE (valbenazine) capsules by the FDA. This approval provides an alternative option for patients with dysphagia or who have difficulty swallowing. 
At the end of April, Neurocrine...
05/15/2024
Psych Congress Network
TD Has ‘Severe Impact’ on Patients and Caregivers
News
TD Has ‘Severe Impact’ on Patients and Caregivers
05/10/2024
Tardive dyskinesia (TD) was found to have a “severe impact” on the lives of both patients and their caregivers across physical, psychological, and social domains. Results from the survey-based study were published in the Journal of Patient...
Tardive dyskinesia (TD) was found to have a “severe impact” on the lives of both patients and their caregivers across physical, psychological, and social domains. Results from the survey-based study were published in the Journal of Patient...
Tardive dyskinesia (TD) was...
05/10/2024
Psych Congress Network
Geriatric Patient with son in long term care setting
News
High Comorbidity, Polypharmacy Burden in Patients With Tardive Dyskinesia in LTC Settings
05/07/2024
Patients with tardive dyskinesia (TD) in long-term care settings have a high comorbidity and polypharmacy burden, with half taking medications that may worsen TD, according to a poster presentation at the APA annual meeting.
Patients with tardive dyskinesia (TD) in long-term care settings have a high comorbidity and polypharmacy burden, with half taking medications that may worsen TD, according to a poster presentation at the APA annual meeting.
Patients with tardive dyskinesia...
05/07/2024
Psych Congress Network
Elderly patient and his doctor
News
Awareness of TD Symptoms Linked With Poorer Health, Social Functioning in Patients
05/15/2023
Clinician-confirmed possible tardive dyskinesia (TD) was associated with diminished wellness and social functioning in real-world patients, according to a study published online in the Journal of Patient-Reported Outcomes.
Clinician-confirmed possible tardive dyskinesia (TD) was associated with diminished wellness and social functioning in real-world patients, according to a study published online in the Journal of Patient-Reported Outcomes.
Clinician-confirmed possible...
05/15/2023
Psych Congress Network
News
Valbenazine Use for Tardive Dyskinesia in Older Adults Proves Efficacious
12/08/2021
Valbenazine use for tardive dyskinesia (TD) in adults aged 65 and older has been deemed efficacious with comparable outcomes to younger adults, according to a post hoc analysis.
Valbenazine use for tardive dyskinesia (TD) in adults aged 65 and older has been deemed efficacious with comparable outcomes to younger adults, according to a post hoc analysis.
Valbenazine use for tardive...
12/08/2021
Psych Congress Network
News
Deutetrabenazine is Beneficial for Long-Term Tardive Dyskinesia Treatment
12/03/2021
Deutetrabenazine may provide long-term treatment benefits to patients with tardive dyskinesia (TD), according to a post hoc analysis presented in a poster at Psych Congress 2021.
Deutetrabenazine may provide long-term treatment benefits to patients with tardive dyskinesia (TD), according to a post hoc analysis presented in a poster at Psych Congress 2021.
Deutetrabenazine may provide...
12/03/2021
Psych Congress Network
News
Individual Titration of Deutetrabenazine Beneficial for Patients With Tardive Dyskinesia
11/17/2021
Response-driven titration of deutetrabenazine is beneficial for patients with tardive dyskinesia (TD), according to new findings.
Response-driven titration of deutetrabenazine is beneficial for patients with tardive dyskinesia (TD), according to new findings.
Response-driven titration of...
11/17/2021
Psych Congress Network
News
Tardive Dyskinesia Creates Physical, Psychological, and Social Burden
11/12/2021
Tardive dyskinesia negatively impacts patients’ physical functioning, mental well-being, and social activities—even in patients with self-assessed mild-to-moderate symptoms.
Tardive dyskinesia negatively impacts patients’ physical functioning, mental well-being, and social activities—even in patients with self-assessed mild-to-moderate symptoms.
Tardive dyskinesia negatively...
11/12/2021
Psych Congress Network
News
Potential NDMAR Antibody-Associated Mechanism in Orofacial Tardive Dyskinesia
09/01/2021
Antibodies against neuronal N-methyl-D-aspartate receptor (NMDAR) may be associated with orofacial tardive dyskinesia (TD) and could potentially be mediated by increased choroid plexus (CP) volume.
Antibodies against neuronal N-methyl-D-aspartate receptor (NMDAR) may be associated with orofacial tardive dyskinesia (TD) and could potentially be mediated by increased choroid plexus (CP) volume.
Antibodies against neuronal...
09/01/2021
Psych Congress Network
A person holds a cannabis joint in their hands
News
Cannabis Use Linked With Diminished Brain Activation in Young Adults
02/11/2025
A lifetime history of heavy cannabis use in young adults was associated with lower brain activation during a working memory task, according to a study in JAMA Network Open
A lifetime history of heavy cannabis use in young adults was associated with lower brain activation during a working memory task, according to a study in JAMA Network Open
A lifetime history of heavy...
02/11/2025
Neurology
Methylphenidate Improved Driving Performance in Adults
News
Methylphenidate Improved Driving Performance in Adults
02/10/2025
Methylphenidate improved driving performance in adults by reducing lane weaving and speed variation, according to results from a recent randomized controlled trial published in the Journal of Psychopharmacology. 
Methylphenidate improved driving performance in adults by reducing lane weaving and speed variation, according to results from a recent randomized controlled trial published in the Journal of Psychopharmacology. 
Methylphenidate improved driving...
02/10/2025
Psych Congress Network
News
90% ROI on Mental Health Benefits
02/07/2025
A recent study published in JAMA Network Open highlights the financial benefits of employer-sponsored behavioral health programs, demonstrating that these programs can result in significant net medical costs savings.
A recent study published in JAMA Network Open highlights the financial benefits of employer-sponsored behavioral health programs, demonstrating that these programs can result in significant net medical costs savings.
A recent study published in JAMA...
02/07/2025
First Report Managed Care
A woman holds her forehead looking stressed
News
Neuroinflammatory Marker Linked to Suicidal Thoughts in Depressed Patients
02/03/2025
Elevated translocator protein (TSPO) binding, a marker of neuroinflammatory processes, was associated with more pronounced daily suicidal ideation and negative affect during real-world stress in patients with major depressive disorder (MDD).
Elevated translocator protein (TSPO) binding, a marker of neuroinflammatory processes, was associated with more pronounced daily suicidal ideation and negative affect during real-world stress in patients with major depressive disorder (MDD).
Elevated translocator protein...
02/03/2025
Psych Congress Network
Drug Overdose Deaths Overall Decrease from 2022 to 2023
News
Drug Overdose Deaths Overall Decrease from 2022 to 2023
01/31/2025
A recent report from the National Center for Health Statistics found many decreases in drug overdose deaths between 2022 and 2023, though certain subsections remained stable or increased year over year, according to the CDC and the National...
A recent report from the National Center for Health Statistics found many decreases in drug overdose deaths between 2022 and 2023, though certain subsections remained stable or increased year over year, according to the CDC and the National...
A recent report from the...
01/31/2025
Psych Congress Network
FDA building
News
FDA Approves Once-Monthly Lecanemab-irmb Dosing for Early Alzheimer Disease
01/28/2025
The FDA has approved a supplemental biologics license application for lecanemab-irmb (Leqembi, Eisai Co., Ltd.; Biogen Inc.), an intravenous treatment (IV) for early Alzheimer disease (AD).
The FDA has approved a supplemental biologics license application for lecanemab-irmb (Leqembi, Eisai Co., Ltd.; Biogen Inc.), an intravenous treatment (IV) for early Alzheimer disease (AD).
The FDA has approved a...
01/28/2025
Psych Congress Network
Brexpiprazole and Sertraline Combination Treatment Improves PTSD Symptoms
News
Brexpiprazole and Sertraline Combination Treatment Improves PTSD Symptoms
01/27/2025
Combining brexpiprazole and sertraline in treatment of post-traumatic stress disorder (PTSD) significantly improved PTSD symptoms when compared with sertraline and placebo treatment, according to results from a randomized clinical trial...
Combining brexpiprazole and sertraline in treatment of post-traumatic stress disorder (PTSD) significantly improved PTSD symptoms when compared with sertraline and placebo treatment, according to results from a randomized clinical trial...
Combining brexpiprazole and...
01/27/2025
Psych Congress Network
IED Linked With Multiple Psychiatric, Neurologic Comorbidities
News
IED Linked With Multiple Psychiatric, Neurologic Comorbidities
01/24/2025
Intermittent explosive disorder (IED) was found to have many comorbidities, including substance use disorder, neurodegenerative diseases, sleep disorders, and many somatic diseases, according to a recent cohort study published in JAMA...
Intermittent explosive disorder (IED) was found to have many comorbidities, including substance use disorder, neurodegenerative diseases, sleep disorders, and many somatic diseases, according to a recent cohort study published in JAMA...
Intermittent explosive disorder...
01/24/2025
Psych Congress Network
ADHD Symptoms Associated With Lower Academic Performance in College Students
News
ADHD Symptoms Associated With Lower Academic Performance in College Students
01/23/2025
Symptoms of attention-deficit/hyperactivity disorder (ADHD) were associated with a lower academic performance in college students, especially those with inattention symptoms, according to a recent systematic review published in the Journal of...
Symptoms of attention-deficit/hyperactivity disorder (ADHD) were associated with a lower academic performance in college students, especially those with inattention symptoms, according to a recent systematic review published in the Journal of...
Symptoms of...
01/23/2025
Psych Congress Network
Some Psychedelics Could Hold Promise for OUD Treatment
News
Some Psychedelics Could Hold Promise for OUD Treatment
01/23/2025
Psychedelics could be a promising treatment option for patients with opioid use disorder (OUD), according to a recent systematic review of preclinical animal studies published in Cellular and Molecular Life Sciences.
Psychedelics could be a promising treatment option for patients with opioid use disorder (OUD), according to a recent systematic review of preclinical animal studies published in Cellular and Molecular Life Sciences.
Psychedelics could be a...
01/23/2025
Psych Congress Network

Interactive Features

amber hoberg, np
Expert Insights Quiz
What screeners should be used to diagnose tardive dyskinesia?
05/26/2023
True or False: According to Nurse Amber Hoberg, the AIMS is the only scale that should be used when screening a patient for tardive dyskinesia (TD).
True or False: According to Nurse Amber Hoberg, the AIMS is the only scale that should be used when screening a patient for tardive dyskinesia (TD).
True or False: According to...
05/26/2023
Psych Congress Network
quiz
Expert Insights Quiz
How does tardive dyskinesia impact medication adherence?
02/14/2023
True or false: Patients with Tardive Dyskinesia (TD) have high rates of antipsychotic medication non-adherence partly due to their TD symptoms.
True or false: Patients with Tardive Dyskinesia (TD) have high rates of antipsychotic medication non-adherence partly due to their TD symptoms.
True or false: Patients with...
02/14/2023
Psych Congress Network
Chepke
Expert Insights Quiz
What is the next step if a patient taking antipsychotics exhibits excessive blink rate?
12/16/2022
As a clinician, if you notice a patient who is taking antipsychotics is exhibiting an excessive blink rate, what should the next step be?
As a clinician, if you notice a patient who is taking antipsychotics is exhibiting an excessive blink rate, what should the next step be?
As a clinician, if you notice a...
12/16/2022
Psych Congress Network
tardive-dyskinesia-quiz
Quiz
The Impact of Tardive Dyskinesia Across Lifestyle Domains
12/10/2021
What percentage of patients with tardive dyskinesia reported their illness having a severe impact across their physical, psychological, and social lives? Take the quiz!
What percentage of patients with tardive dyskinesia reported their illness having a severe impact across their physical, psychological, and social lives? Take the quiz!
What percentage of patients with...
12/10/2021
Psych Congress Network
Quiz
Can long-term anticholinergic medication exposure cause long-term consequences?
10/28/2021
True or false: Long-term anticholinergic medication exposure can cause long-term consequences that surpass previously documented short-term cognitive effects.
True or false: Long-term anticholinergic medication exposure can cause long-term consequences that surpass previously documented short-term cognitive effects.
True or false: Long-term...
10/28/2021
Psych Congress Network
Quiz
Antibody Levels in Schizophrenia Patients With Tardive Dyskinesia
10/15/2021
According to a recent study, what antibody levels were significantly higher in schizophrenia patients with tardive dyskinesia (TD)? Take the quiz to find out!
According to a recent study, what antibody levels were significantly higher in schizophrenia patients with tardive dyskinesia (TD)? Take the quiz to find out!
According to a recent study,...
10/15/2021
Psych Congress Network
Quiz
Quiz: Are These Antibodies Associated with Orofacial Tardive Dyskinesia?
09/09/2021
True or False: A notable percentage of psychiatrists said they would use an anticholinergic medication to manage symptoms of tardive dyskinesia in a patient.
True or False: A notable percentage of psychiatrists said they would use an anticholinergic medication to manage symptoms of tardive dyskinesia in a patient.
True or False: A notable...
09/09/2021
Psych Congress Network
Bottles
Quiz
Updated Treatments for Tardive Dyskinesia
08/16/2021
What are the updated treatments for tardive dyskinesia? Take the quiz and find out!
What are the updated treatments for tardive dyskinesia? Take the quiz and find out!
What are the updated treatments...
08/16/2021
Psych Congress Network
quiz
Quiz
Did psychiatrists say they would use anticholinergic medication for TD treatment?
06/17/2021
True or False: A notable percentage of psychiatrists said they would use an anticholinergic medication to manage symptoms of tardive dyskinesia in a patient.
True or False: A notable percentage of psychiatrists said they would use an anticholinergic medication to manage symptoms of tardive dyskinesia in a patient.
True or False: A notable...
06/17/2021
Psych Congress Network
Quiz
How Often Should Patients Be Evaluated for Tardive Dyskinesia?
05/07/2021
Test your knowledge: How often does the American Psychiatric Association (APA) recommend patients taking either first or second-generation antipsychotics be assessed for tardive dyskinesia?
Test your knowledge: How often does the American Psychiatric Association (APA) recommend patients taking either first or second-generation antipsychotics be assessed for tardive dyskinesia?
Test your knowledge: How often...
05/07/2021
Psych Congress Network
How many US Psychiatric Hospitals Provided Medications for OUD?
Quiz
How many US psychiatric hospitals provided medications for OUD?
02/06/2025
Do you remember the details of this study?
Do you remember the details of this study?
Do you remember the details of...
02/06/2025
Psych Congress Network
Four people ponder with question marks over their heads
Quiz
DSM-5 Quiz: Mood Symptoms in Schizophrenia
02/03/2025
Test your knowledge with this quick quiz!
Test your knowledge with this quick quiz!
Test your knowledge with this...
02/03/2025
Psych Congress Network
How many people with anxiety disorders receive treatment?
Quiz
How many people with anxiety disorders receive treatment?
01/28/2025
Test your statistical knowledge!
Test your statistical knowledge!
Test your statistical knowledge!
01/28/2025
Psych Congress Network
How can clinicians help patients with ADHD transition from adolescence to adulthood?
Quiz
How can clinicians help patients with ADHD transition from adolescence to adulthood?
01/22/2025
Do you remember this interview with Dr Wilens?
Do you remember this interview with Dr Wilens?
Do you remember this interview...
01/22/2025
Psych Congress Network
Three illustrated faces, one sad, one neutral, one happy, with a human hand picking up the happy face
Quiz
Conditions That Mimic ADHD in Pediatric Patients
01/21/2025
Test your knowledge with this quiz!
Test your knowledge with this quiz!
Test your knowledge with this...
01/21/2025
Psych Congress Network
Quiz
Quiz
What percentage of people experience hypomanic symptoms during an MDD episode?
01/15/2025
According to a recent study published in the Journal of Affective Disorders, what percentage of people experienced hypomanic symptoms during a major depressive disorder (MDD) episode?
According to a recent study published in the Journal of Affective Disorders, what percentage of people experienced hypomanic symptoms during a major depressive disorder (MDD) episode?
According to a recent study...
01/15/2025
Psych Congress Network
Which U.S. region saw the most fentanyl pill seizures in 2023?
Quiz
Which US region saw the most fentanyl pill seizures in 2023?
01/15/2025
Do you remember the details of this study?
Do you remember the details of this study?
Do you remember the details of...
01/15/2025
Psych Congress Network
An illustration of a pencil marking answers on a quiz sheet.
Expert Insights Quiz
Resources for Telehealth Rules and Regulations
01/06/2025
Test your knowledge with this quiz!
Test your knowledge with this quiz!
Test your knowledge with this...
01/06/2025
Psych Congress Network
How long does worry need to be present in order to diagnose GAD?
Quiz
How long does worry need to be present in order to diagnose GAD?
01/03/2025
Test your diagnostic knowledge!
Test your diagnostic knowledge!
Test your diagnostic knowledge!
01/03/2025
Psych Congress Network
Pop quiz written on a blackboard with white chalk
Quiz
Antidepressant Discontinuation Symptoms
12/23/2024
Test your knowledge with this quick quiz!
Test your knowledge with this quick quiz!
Test your knowledge with this...
12/23/2024
Psych Congress Network

Posters

Clinical effectiveness and persistence on esketamine nasal spray in patients with treatment-resistant depression overall and among transcranial magnetic stimulation-naïve subgroup
BACKGROUND: Esketamine nasal spray and transcranial magnetic stimulation (TMS) are used for treatment-resistant depression (TRD), but little is known about the sequence in which these the...
11/26/2024
Real-world clinical effectiveness of esketamine nasal spray based on the Montgomery-Asberg Depression Rating Scale (MADRS) among patients with treatment-resistant depression in the United States
BACKGROUND: Clinical trials for esketamine nasal spray in treatment resistant depression (TRD) often assess efficacy using Montgomery-Asberg Depression Rating Scale (MADRS)-based primary ...
11/26/2024
Response and remission on esketamine nasal spray in patients with treatment-resistant depression overall and among transcranial magnetic stimulation-naïve subgroup
BACKGROUND: Both esketamine nasal spray and transcranial magnetic stimulation (TMS) are indicated for treatment-resistant depression (TRD), but there are no guidelines on the sequence of...
11/26/2024
Comparison of Real-world Response and Remission among Patients with Treatment-Resistant Depression Treated with Esketamine Nasal Spray or Antipsychotic Augmentation
BACKGROUND: Esketamine nasal spray and second-generation antipsychotic augmentation (SGA) are approved therapies for treatment-resistant depression (TRD). Prospective randomized ESCAPE-TR...
11/26/2024
Effect of Centanafadine on AISRS Over 6 Weeks of Treatment in Adults with ADHD: A Pooled Analysis of Two Phase 3 Trials
TBD
11/26/2024
Impact of Centanafadine on the ASRS After 6 Weeks of Treatment of ADHD in Adults: A Pooled Analysis of Two Phase 3 Trials
Hypothesis/Objective: To evaluate the impact of centanafadine (CTN)—a norepinephrine, dopamine, serotonin reuptake inhibitor—on patient-reported assessment of the frequency of core sympto...
11/26/2024
Adjunctive Treatment With Seltorexant Improved Patient-Reported Depressive Symptoms, Insomnia Symptoms, and Overall Health in Major Depressive Disorder With Insomnia
Background: We report secondary/exploratory endpoints assessing patient-reported depressive symptoms, insomnia symptoms, and health-related quality of life (HRQoL) from a phase 3, double-...
11/26/2024
Guiding antidepressant choice by applying deep learning approaches on individual patient-derived neurons: a window to drug efficacy in each patient
Depression treatment remains a significant clinical challenge due to the variability in patient responses to antidepressant medications. Outside of pharmacogenetic testing, established mo...
11/26/2024
Lumateperone in the Treatment of Major Depressive Disorder and Bipolar Depression With Mixed Features: Efficacy Across Symptoms
Introduction: Lumateperone is an FDA-approved antipsychotic to treat schizophrenia and depressive episodes associated with bipolar I or II disorder. This prospectively defined analysis of...
11/26/2024
Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial
Introduction: Lumateperone is an FDA-approved antipsychotic to treat schizophrenia and bipolar depression. This Phase 3, randomized, double-blind, placebo-controlled, multicenter, interna...
11/26/2024

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use